Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA025
- Development stage
- Preclinical
- Lead developer
- SmartNuclide
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SNA025 is a preclinical-stage theranostic radiopharmaceutical being developed by SmartNuclide (Suzhou SmartNuclide Biopharmaceutical Co., Ltd.). It is designed as a radionuclide drug conjugate that utilizes single-domain antibody (nanobody) technology to target the disialoganglioside GD2. GD2 is a ganglioside highly expressed on various solid tumors, including neuroblastoma, melanoma, and certain sarcomas, while maintaining restricted expression in normal tissues. SNA025 is engineered to deliver therapeutic radionuclides, specifically the beta-emitter lutetium-177 (177Lu) or the alpha-emitter actinium-225 (225Ac), directly to tumor sites for targeted cytotoxicity. As a theranostic agent, it is intended to facilitate both diagnostic imaging and therapeutic intervention using the same targeting platform.
- Other names
- SNA025-SmartNuclide-GD2-radiopharmaceuticalSNA-025-SmartNuclide-GD2-radiopharmaceuticalSNA 025-SmartNuclide-GD2-radiopharmaceutical
02
Targets
GD2
Beyond the preview
Go deeper on SNA025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA025.